[Clinical Trial News] DESTINY-Breast03 in ASCO 2022

DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?

Click the link below to read more:

https://ascopost.com/issues/june-10-2022/destiny-breast03-should-trastuzumab-deruxtecan-be-the-preferred-second-line-regimen-in-her2-positive-metastatic-breast-cancer/?utm_source=pushly&fbclid=IwAR2b4UO94IGDCbb1BUbnY_amAbn9Tqm8BmO8NuCLozUvJQX6Dt4kiKVwvI4